
    
      The purpose of this study is to evaluate the safety, tolerance and efficacy of Liposomal
      Paclitaxel With Nedaplatin as First-line in patients with Advanced or Recurrent Esophageal
      Carcinoma.Patients receive Liposomal Paclitaxel 175mg/m2 and Nedaplatin 80mg/m2 every 21 days
      until the presence of progressive disease or unacceptable toxicity.
    
  